The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Kidney Transplantation in Highly Sensitized Patients
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
-
University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States, 35249
John Hopkins Hospital, Baltimore, Maryland, United States, 21287
New York University (NYU) Langone Transplant Institute, NYU Langone Health, New York, New York, United States, 10016
Columbia University, New York, New York, United States, 10032
Houston Methodist Hospital, Houston, Texas, United States, 77030
Methodist Hospital Specialty and Transplant, San Antonio, Texas, United States, 78229
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
Hansa Biopharma AB,
Therese Åkerfeldt, STUDY_DIRECTOR, Hansa Biopharma AB
2029-12-31